🇺🇸 long-acting beta-agonists in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 9

Most-reported reactions

1. Acute Myocardial Infarction — 1 report (11.11%)
2. Brain Neoplasm — 1 report (11.11%)
3. Cardiovascular Disorder — 1 report (11.11%)
4. Condition Aggravated — 1 report (11.11%)
5. Death — 1 report (11.11%)
6. Deep Vein Thrombosis — 1 report (11.11%)
7. Mental Disorder — 1 report (11.11%)
8. Respiratory Disorder — 1 report (11.11%)
9. Weight Decreased — 1 report (11.11%)

Source database →

Frequently asked questions

Is long-acting beta-agonists approved in United States?

long-acting beta-agonists does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for long-acting beta-agonists in United States?

Genentech, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.